6月15日-21日，全球共达成8项资产授权与合作交易。中国医药市场仅有1项出海交易。Day One Biopharma和麦科思生物就后者一临床前资产PTK7 ADC达成授权交易，首付款5500万美元，总金额12.07亿美元。
国际市场上，共签署了7项资产授权与合作交易。其中最值得关注的交易是Roche与Ascidian之间签署的基于RNA外显子编辑技术的合作，首付款4200万美元，总金额18.42亿美元。
From June 15 to 21, a total of eight licensing and cooperation deals were signed globally. In the China Biotech Industry, there was one out-licensing deal between MabCare Therapeutics and Day One Biopharma for a pre-clinical stage asset, totaling $1.207 billion with an upfront payment of $55 million.
Globally, seven licensing and cooperation deals were sealed. The standout deal of the week was between Ascidian Therapeutics and Roche for RNA exon editing technology, amounting to a total of $1.842 billion with an upfront payment of $42 million.
2b. Global section
3. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit www.yafocapital.com
Event Name: ACCESS CHINA Networking & Gathering @BIO
